155 results
Page 4 of 8
8-K
EX-99.1
ympamnna
11 Jan 22
Regulation FD Disclosure
12:00am
8-K
EX-99.1
l68o5c he2mi5dbqe1
15 Dec 21
Kiora Pharmaceuticals Appoints David Hollander, MD, MBA, to its Board of Directors
7:00am
8-K
EX-99.1
e9z1j
14 Dec 21
Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye Disease
7:02am
8-K
yvs6ckf3ttnc365dxu0
14 Dec 21
Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye Disease
7:02am
8-K
EX-3.2
ux4mr2lqx8jk5t0 c2hv
8 Nov 21
EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s
7:32am
8-K
EX-99.1
yib5xrp a0nma
8 Nov 21
EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s
7:32am
8-K
EX-2.1
boqtw 1nd
26 Oct 21
EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline
7:00am
8-K
EX-99.1
1d5q07x 3w
26 Oct 21
EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline
7:00am
8-K
EX-99.1
2bvcvz
14 Sep 21
Regulation FD Disclosure
4:20pm
424B5
pjg45a
11 Aug 21
Prospectus supplement for primary offering
6:56am
8-K
EX-10.1
ahoe4 og1
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-99.1
bceo q6l8o5
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-99.1
h1tywk rgcj
26 Jul 21
EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer
4:18pm
8-K
EX-99.1
mco8x7zw cl
27 May 21
Regulation FD Disclosure
7:01am
424B3
bdzk8bov53fu j6l
30 Apr 21
Prospectus supplement
5:01pm